Ads
related to: editas stock
Search results
Is Editas Medicine Stock a Buy Now?
Motley Fool· 11 months agoInvestors tend to move away from somewhat speculative stocks when the economic going gets rough. Editas Medicine's most advanced candidate is EDIT-301,...
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Motley Fool· 1 year agoEditas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing...
Where Will Editas Medicine Be in 1 Year?
Motley Fool· 2 years agoGene-editing specialist Editas Medicine (NASDAQ: EDIT) fits the bill, which is why the company's shares have plunged this year. Could this be what's in...
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
Motley Fool· 1 year agoAfter a tumultuous 2022, growth stocks have started to regain their footing in 2023. Small- and...
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
Simply Wall St. via Yahoo Finance· 3 weeks agoKey Insights Significantly high institutional ownership implies Editas Medicine's stock price is...
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool via Yahoo Finance· 4 months agoEditas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few...
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 months agoEditas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript February 28, 2024 Editas...
Are Institutions Heavily Invested In Editas Medicine, Inc.'s (NASDAQ:EDIT) Shares?
Simply Wall St. via Yahoo Finance· 2 years agoIf you want to know who really controls Editas Medicine, Inc. (NASDAQ:EDIT), then you'll have to...
Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ...
GuruFocus.com via Yahoo Finance· 7 months agoEditas Medicine Inc (NASDAQ:EDIT) reports a net loss of $45.0 million for Q3 2023, down from $55.7...
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
Motley Fool· 8 months agoIf you've ever thought about investing in the gene-editing biotech space, Editas Medicine (NASDAQ:...